IPO
Rezera files for $181M IPO to fund phase 3 trial of NLRP3 inhibitor ruvonoflast
Key Facts
Signal Type
IPO
Industry
Biotech
Companies
Rezera, NodThera, Novo
Date
Rezera, the rebranded successor to NodThera, filed an SEC registration for a $181 million IPO to fund a phase 3 trial of its NLRP3 inhibitor ruvonoflast for peripheral artery disease (PAD). The offering includes 16.7 million shares priced between $11 and $13, with potential additional proceeds if underwriters exercise their option. The company plans to start the phase 3 study next year and expects a readout in 2028.
Rezera, a Boston-based biotech with a UK office in Cambridge, employs only 21 full-time staff and holds $3.9 million in cash. The IPO directly impacts the company's ability to scale clinical operations, regulatory functions, and commercial readiness. The approximately 20 million US adults with PAD represent the target patient population for ruvonoflast.
Rezera is targeting a $5 billion market opportunity in PAD, a large unmet need with high inflammatory burden. The IPO proceeds are primarily allocated to the phase 3 trial, with limited funds currently available for a second drug candidate (trabzanoflast) or commercial launch preparations. This creates a near-term need for:
Monitor the final IPO pricing and whether underwriters exercise their option, as additional proceeds could fund the second NLRP3 inhibitor’s phase 2 trial. Also watch for hiring announcements and vendor contract awards as Rezera ramps up for the phase 3 launch. The company’s rebrand and IPO timing signal organizational growth that typically triggers vendor selection cycles.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
